Ken Griffin Affimed N.V. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.32 - $0.62 $2,560 - $4,960
-8,000 Reduced 81.63%
1,800 $1,000
Q3 2023

Nov 14, 2023
SELL
$0.46 - $0.65 $1,518 - $2,145
-3,300 Reduced 25.19%
9,800 $4,000
Q2 2023

Aug 14, 2023
BUY
$0.57 - $1.08 $7,466 - $14,148
13,100 New
13,100 $7,000
Q4 2022

Feb 14, 2023
SELL
$1.1 - $2.45 $11,110 - $24,745
-10,100 Reduced 61.96%
6,200 $7,000
Q3 2022

Nov 14, 2022
SELL
$1.96 - $3.32 $28,224 - $47,808
-14,400 Reduced 46.91%
16,300 $34,000

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email